Generic Name: enfortumab vedotin-ejfv
Drug Class: Targeted Therapy Medications
Company: Astellas/Seattle Genetics
Approval Status: Approved
Generic Version Available: No
Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.
Padcev consists of an antibody that targets nectin-4, a protein found at high levels on most urothelial cancer cells, which delivers a chemotherapy drug (monomethyl auristantin E) that prevents cell division.
The Phase II EV-120 clinical trial showed that 44% of people with advanced urothelial cancer who were previously treated with checkpoint inhibitors and platinum chemotherapy responded to Padcev, including 12% with complete remission. Padcev was first approved in December 2019.
Padcev is administered by intravenous infusion.
Common side effects include fatigue, peripheral neuropathy, decreased appetite, skin rash, hair loss, nausea, dysgeusia (altered taste sensations), diarrhea, dry eyes, dry skin and itching. Potentially serious adverse events may include severe hyperglycemia (high blood sugar), severe peripheral neuropathy, eye disorders and severe skin reactions. Padcev may cause fetal harm if used during pregnancy.
Last Reviewed: December 18, 2019